English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Preclinical assessment of drug-induced proarrhythmicity is typically evaluated by the potency of the drug to block the potassium human ether-à-go-go-related gene (hERG) channels, which is currently quantified by the IC 50 . However, channel block depends on the experimental conditions. Our aim is to improve the evaluation of the blocking potency of drugs by designing experimental stimulation protocols to measure the IC 50 that will help to decide whether the IC 50 is representative enough. We used the state-of-the-art mathematical models of the cardiac electrophysiological activity to design three stimulation protocols that enhance the differences in the probabilities to occupy a certain conformational state of the channel and, therefore, the potential differences in the blocking effects of a compound. We simulated an extensive set of 144 in silico I  Kr blockers with different kinetics and affinities to conformational states of the channel and we also experimentally validated our key predictions. Our results show that the IC 50 protocol dependency relied on the tested compounds. Some of them showed no differences or small differences on the IC 50 value, which suggests that the IC 50 could be a good indicator of the blocking potency in these cases. However, others provided highly protocol dependent IC 50 values, which could differ by even 2 orders of magnitude. Moreover, the protocols yielding the maximum IC 50 and minimum IC 50 depended on the drug, which complicates the definition of a "standard" protocol to minimize the influence of the stimulation protocol on the IC 50 measurement in safety pharmacology. As a conclusion, we propose the adoption of our three-protocol IC 50 assay to estimate the potency to block hERG in vitro. If the IC 50 values obtained for a compound are similar, then the IC 50 could be used as an indicator of its blocking potency, otherwise kinetics and state-dependent binding properties should be accounted.

When Does the IC50 Accurately Assess the Blocking Potency of a Drug?

When Does the IC₅₀ Accurately Assess the Blocking Potency of a Drug?